Cited by 134Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

Open access
Chiou, Shin-Heng, Tseng, Diane, Reuben, Alexandre, Mallajosyula, Vamsee, Molina, Irene S., Conley, Stephanie, Wilhelmy, Julie, McSween, Alana M. +32 more·2021·Immunity

Abstract

To identify disease-relevant T cell receptors (TCRs) with shared antigen specificity, we analyzed 778,938 TCRβ chain sequences from 178 non-small cell lung cancer patients using the GLIPH2 (grouping of lymphocyte interactions with paratope hotspots 2) algorithm. We identified over 66,000 shared specificity groups, of which 435 were clonally expanded and enriched in tumors compared to adjacent lung. The antigenic epitopes of one such tumor-enriched specificity group were identified using a yeast peptide-HLA A ∗ 02:01 display library. These included a peptide from the epithelial protein TMEM161A, which is overexpressed in tumors and cross-reactive epitopes from Epstein-Barr virus and E. coli . Our findings suggest that this cross-reactivity may underlie the presence of virus-specific T cells in tumor infiltrates and that pathogen cross-reactivity may be a feature of multiple cancers. The approach and analytical pipelines generated in this work, as well as the specificity groups defined here, present a resource for understanding the T cell response in cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2021.02.014

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 77 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., Sinha, R., Nabet, B. Y., Wang, C., Shrager, J. B., Berry, M. F., Backhus, L., Lui, N. S., Wakelee, H. A., Neal, J. W., Padda, S. K., Berry, G. J., Delaidelli, A., Sorensen, P. H., Sotillo, E., Tran, P., Benson, J. A., Richards, R., Labanieh, L., Klysz, D. D., Louis, D. M., Feldman, S. A., Diehn, M., Weissman, I. L., Zhang, J., Wistuba, I. I., Futreal, P. A., Heymach, J. V., Garcia, K. C., Mackall, C. L., & Davis, M. M.
Affiliations
  • Stanford University (US)
  • Stanford Medicine (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Rutgers, The State University of New Jersey (US)
  • Institute for Stem Cell Biology and Regenerative Medicine (US)
  • BC Cancer Agency (CA)
  • Stanford Cancer Institute (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Davis, Mark M.
Venue
Immunity
Publisher
Elsevier BV
Published
2021-03
Volume
54
Issue
3
Pages
586-602.e8
ISSN
1074-7613 (ISSN-L)
OpenAlex
W3134245065
Cited by
133
References
77
Citations by year
2026: 20 · 2025: 19 · 2024: 26 · 2023: 28 · 2022: 29 · 2021: 10 · 2020: 1
FWCI
8.56
Type
journal article
Language
en
Open access
Locations
  • Immunity (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Rutgers University Community Repository (Rutgers University) (submittedVersion)
Funders
  • NCI Cancer Moonshot
  • Stand up to Cancer
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
non-small cell lung cancer, T cell clones, cross-reactive epitopes, Epstein-Barr virus, Escherichia coli, virus-specific T cells, tumor immunology
MeSH terms
Algorithms, Antigens, Neoplasm, Carcinoma, Non-Small-Cell Lung, Cells, Cultured, Cross Reactions, Humans, Lung Neoplasms, Protein Binding, T-Lymphocytes, HLA-A2 Antigen, Receptors, Antigen, T-Cell, alpha-beta, Antigen Presentation, Epitope Mapping, Epitopes, T-Lymphocyte, T-Cell Antigen Receptor Specificity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review